NCT04645368 is a clinical trial of bovhyaluronidase azoxymer in Fibroses, Pulmonary, sponsored by NPO Petrovax.

Who is sponsoring NCT04645368?

NCT04645368 is sponsored by NPO Petrovax.

What drugs are being tested in NCT04645368?

Interventions in NCT04645368: bovhyaluronidase azoxymer.

What condition does NCT04645368 study?

NCT04645368 studies Fibroses, Pulmonary.

Is NCT04645368 still recruiting?

NCT04645368 is currently completed. Last updated 23 April 2024.

Last reviewed 2024-04-23 · How we verify

NCT04645368

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Longidaze in the Prevention & Treatment of Pulmonary Fibrosis, Interstitial Lung Diseases Caused by COVID-19

Completed Last updated 23 April 2024

What this trial tests

trial testing bovhyaluronidase azoxymer in Fibroses, Pulmonary in 160 participants. Completed in 20 April 2022.

Timeline

1 July 2020

Primary endpoint
20 April 2022

20 April 2022

Quick facts

Lead sponsor	NPO Petrovax
Status	Completed
Study type	OBSERVATIONAL
Enrollment	160
Start date	1 July 2020
Primary completion	20 April 2022
Estimated completion	20 April 2022
Sites	15 locations across Russia

Drugs / interventions tested

bovhyaluronidase azoxymer — full drug profile →

Conditions studied

Fibroses, Pulmonary — all drugs for Fibroses, Pulmonary →

Sponsor

NPO Petrovax — full company profile →

Who can join

18 and older, any sex, with Fibroses, Pulmonary. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A study is being conducted to evaluate the efficacy and safety of Longidaze for the prevention and treatment of post-inflammatory pulmonary fibrosis and interstitial lung disease following COVID-19.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Lung Fibrosis after COVID-19: Treatment Prospects.
Bazdyrev E, Rusina P, Panova M, Novikov F, et al · · 2021 · cited 123× · PMID 34451904 · DOI 10.3390/ph14080807
COVID-19 and interstitial lung diseases: A multifaceted look at the relationship between the two diseases.
Fukihara J, Kondoh Y. · · 2023 · cited 15× · PMID 37429073 · DOI 10.1016/j.resinv.2023.05.007
COVID-19 and fibrosis: Mechanisms, clinical relevance, and future perspectives.
Saifi MA, Bansod S, Godugu C. · · 2022 · cited 12× · PMID 36075378 · DOI 10.1016/j.drudis.2022.103345
Antifibrotic Drugs against Idiopathic Pulmonary Fibrosis and Pulmonary Fibrosis Induced by COVID-19: Therapeutic Approaches and Potential Diagnostic Biomarkers.
Perez-Favila A, Garza-Veloz I, Hernandez-Marquez LDS, Gutierrez-Vela EF, et al · · 2024 · cited 9× · PMID 38338840 · DOI 10.3390/ijms25031562
Challenges in the Management of Post-COVID-19 Pulmonary Fibrosis for the Latin American Population.
Cherrez-Ojeda I, Cortés-Telles A, Gochicoa-Rangel L, Camacho-Leon G, et al · · 2022 · cited 8× · PMID 36143178 · DOI 10.3390/jpm12091393
Nanotherapeutic Approaches to Treat COVID-19-Induced Pulmonary Fibrosis.
Kanvinde S, Deodhar S, Kulkarni TA, Jogdeo CM. · · 2023 · cited 1× · PMID 37218751 · DOI 10.3390/biotech12020034
Nano-Therapeutic Approaches to Treat COVID Induced Pulmonary Fibrosis
Kanvinde S, Deodhar S, Kulkarni TA, Jogdeo CM. · · 2023 · DOI 10.20944/preprints202303.0472.v1

Verify or expand the search:

Other NPO Petrovax trials

Trials by the same sponsor.

NCT06834100 — Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug · Phase 3 · recruiting
NCT06568718 — Efficacy and Safety of Longidaze in the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyper · NA · completed
NCT06385821 — A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus · Phase 3 · completed
NCT05975879 — A Study of the Feasibility of Using the Dietary Supplement "ARTNEO" in Patients With Osteoathritis · NA · completed
NCT06383819 — Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19 · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04645368 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NPO Petrovax
Last refreshed: 23 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04645368.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing